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OBJECTIVES The primary objective of this study was to determine whether intracoronary administration of
the adenoviral gene for fibroblast growth factor (Ad5FGF-4) can improve myocardial
perfusion compared with placebo.
BACKGROUND Animal studies and observational clinical studies have shown improvement in perfusion of the
ischemic myocardium using genes encoding angiogenic growth factors; however, randomized,
double-blind data in humans are lacking.
METHODS We performed a randomized, double-blind, placebo-controlled trial of intracoronary injection
of 1010 adenoviral particles containing a gene encoding fibroblast growth factor (Ad5FGF-4)
to determine the effect on myocardial perfusion. Fifty-two patients with stable angina and
reversible ischemia comprising9% of the left ventricle on adenosine single-photon emission
computed tomography (SPECT) imaging were randomized to gene therapy (n  35) or
placebo (n  17). Clinical follow-up was performed, and 51 (98%) patients underwent a
second adenosine SPECT scan after 8 weeks.
RESULTS Overall (n  52), the mean total perfusion defect size at baseline was 32.4% of the left
ventricle, with 20% reversible ischemia and 12.5% scar. At eight weeks, Ad5FGF-4 injection
resulted in a significant reduction of ischemic defect size (4.2% absolute, 21% relative; p 
0.001) and placebo-treated patients had no improvement (p 0.32). Although the change in
reversible perfusion defect size between Ad5FGF-4 and placebo was not significant (4.2% vs.
1.6%, p  0.14), when a single outlier was excluded a significant difference was observed
(4.2% vs. 0.8%, p 0.05). Ad5FGF-4 was well tolerated and did not result in any permanent
adverse sequelae.
CONCLUSIONS Intracoronary injection of Ad5FGF-4 showed an encouraging trend for improved myocardial
perfusion; however, further studies of therapeutic angiogenesis with Ad5FGF-4 will be
necessary. (J Am Coll Cardiol 2003;42:1339–47) © 2003 by the American College of
Cardiology Foundation
Myocardial ischemia is a leading cause of death and disabil-
ity in the developed world. Established treatment for
myocardial ischemia has to date consisted of revasculariza-
tion using either percutaneous or surgical techniques to
improve blood supply to the myocardium, or pharmacother-
apy designed to limit myocardial oxygen demand. Many
patients prove to be ineligible or refractory to the conven-
tional therapies, and percutaneous or surgical revasculariza-
tion is associated with a distinct set of risks. Newer
approaches to improve blood flow to the myocardium have
focused on the biology of enhancing growth and the
development of new blood vessels. Despite encouraging
reports from uncontrolled pilot studies, two recent clinical
trials using the angiogenic proteins vascular endothelial
growth factor-165 and basic fibroblast growth factor
(FGF)-2 have reported no significant difference in treadmill
exercise time in patients with severe ischemic heart disease
compared with placebo (1,2). These negative findings may
be due to the short duration of effect of the protein, and may
be overcome by administering the gene, which results in
sustained production of the angiogenic protein. We have
previously shown that intracoronary administration of the
gene encoding FGF-4 delivered using an adenoviral vector
increased treadmill exercise time by 1.5 min compared with
0.9 min in placebo-treated patients with stable angina (3).
An increase of 1 min compared with placebo was observed
From the *Department of Medicine, Section of Cardiology, William Beaumont
Hospital, Royal Oak, Michigan; †Department of Medicine, University of Vermont,
Burlington, Vermont; ‡Department of Medicine, Section of Cardiology, The
Methodist Hospital, Baylor College of Medicine, Houston, Texas; §Department of
Medicine/Section of Cardiology, The University of Alabama at Birmingham,
Birmingham, Alabama; John Hopkins, Baltimore, Maryland; and ¶Berlex Labora-
tories, Montville, New Jersey. Supported by a grant from Berlex Inc, and Collateral
Therapeutics Inc. All authors, except Pran Marrott, received research funding for
AGENT-2.
Manuscript received January 13, 2003; revised manuscript received May 7, 2003,
accepted June 13, 2003.
Journal of the American College of Cardiology Vol. 42, No. 8, 2003
© 2003 by the American College of Cardiology Foundation ISSN 0735-1097/03/$30.00
Published by Elsevier Inc. doi:10.1016/S0735-1097(03)00988-4
12 weeks after treatment using a dose of 1010 viral particles
(3). Although exercise duration is of prognostic importance,
it does not directly measure myocardial perfusion.
Nuclear scintigraphy using quantitative tomographic
techniques is highly accurate and reproducible and is a
reliable indicator of myocardial perfusion (4–7). Moreover,
the size of an ischemic perfusion defect has been shown in
several studies to be a predictor of the risk of adverse cardiac
events over a period of several years (8–11). Therefore,
reduction in ischemic perfusion defect size would provide
evidence that the therapy has increased blood supply to the
myocardium, and may ultimately improve prognosis. Ac-
cordingly, we undertook a randomized, double-blind,
placebo-controlled trial to determine the effects of intra-
coronary administration of adenoviral delivered FGF-4
gene therapy (Ad5FGF-4) on myocardial perfusion mea-
sured as scintigraphic ischemic defect size in patients with
coronary artery disease. We selected a dose of 1010 viral
particles of Ad5FGF-4 based on the findings of Grines et
al. (3).
METHODS
Objectives. The primary objective of this study was to
determine whether intracoronary administration of 1010
viral particles of Ad5FGF-4 could significantly decrease the
size of an adenosine-induced ischemic left ventricular per-
fusion defect size compared with placebo. An important
additional aspect of the primary study objective was to
evaluate the safety of Ad5FGF-4, including specific risks
related to the virus or related to FGF-4.
Study design and population. The study was approved by
the Food and Drug Administration, Recombinant DNA
Advisory Committee, appropriate institutional review
boards and biosafety committees, and was conducted in
accordance with the International Conference on Harmo-
nization and Good Clinical Practice Guidelines. All pa-
tients provided written informed consent. Patients age 30 to
75 years with stable angina (4 weeks, angina class 2 to 4)
who were symptomatic despite using antianginal drugs and
who were not optimal candidates for revascularization by
surgical or percutaneous means were studied. Patients could
have single or multivessel coronary artery disease provided at
least one proximal major vessel (coronary artery or bypass
graft) had 70% stenosis to allow adequate infusion of
study product. Patients were included if left ventricular
ejection fraction determined by gated technetium-99m
(99mTc)-sestamibi single-photon emission computed to-
mography (SPECT) was 30% and adenosine-induced
(ischemic) left ventricular reversible perfusion defect size
(RPDS) was 9%.
Exclusion criteria were as follows: left main coronary
arterial stenosis 70% (unless protected with a patent
graft), bypass surgery within the past 6 months, angioplasty
within 4 months, unstable angina, patients requiring imme-
diate revascularization, myocardial infarction 6 weeks,
chronic heart failure (class 4), chronic atrial fibrillation/
flutter, human immunodeficiency virus (HIV) positive,
chronic immunosuppressive therapy, hepatic disease, and
previous administration of any gene product or growth
factor protein. Other exclusions were type 1 diabetes,
patients with severe pre-proliferative or proliferative reti-
nopathy, malignant tumors within the past 10 years, throm-
bocytopenia (130  103/l), use of abciximab within 30
days, patients of child-bearing potential, and patients in
whom adenosine administration was contraindicated.
Screening. Baseline observations and tests included his-
tory, physical, and ophthalmic examination, 99mTc-
sestamibi gated SPECT imaging at rest and after pharma-
cologic stress with adenosine, Duke Activity Status Index
(administered by the same person for a given patient
throughout the study), assessment of angina class, diary for
noting angina attacks and nitroglycerin use, clinical hema-
tology, blood chemistry, liver function tests, urinalysis,
HIV, tests for hepatitis B and C, troponin T, creatine kinase
(CK)-myoglobin fraction and CK (isoenzyme), serum
FGF-4 level, tumor screening involving history, physical,
rectal, and pelvic examination, Papanicolaou smear and
mammogram (women), prostate-specific antigen (men),
stool for occult blood, proctosigmoidoscopy or colonoscopy
if indicated, and other tests as necessary. Specialist opinion
was obtained to evaluate abnormal symptoms, signs, or tests
suspicious of malignancy.
Gene product preparation and administration. The
Ad5FGF-4 gene consists of a recombinant human adeno-
virus (serotype 5) made replication-deficient by the deletion
of E1A/E1B genes that are replaced by the human FGF-4
gene, driven by a cytomegalovirus promoter.
After the completion of baseline observations and tests,
patients fulfilling the entry criteria were randomized (in the
ratio of two active to one placebo) to receive intracoronary
Ad5FGF-4 or matching placebo (vehicle) in a double-blind
manner. A coronary angiogram was undertaken before study
product administration to confirm the suitability of coronary
anatomy. Ad5FGF-4 (1010 viral particles) or matching
placebo diluted with normal saline to 5 or 10 ml was
administered by intracoronary injections (60% in the left
and 40% in the right coronary systems) over a period of 90 s
into each target coronary artery or patent bypass graft. In
Abbreviations and Acronyms
ANOVA  analysis of variance
CABG  coronary artery bypass graft
CK  creatine kinase
FGF  fibroblast growth factor
HIV  human immunodeficiency virus
RPDS  reversible perfusion defect size
SGOT  serum glutamic-oxaloacetic transaminase
SGPT  serum glutamic-pyruvic transaminase
SPECT  single-photon emission computed
tomography
99mTc  technetium-99m
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patients with previous coronary artery bypass surgery, the
distribution of the study agent was determined on the basis
of the operator’s estimation of the distribution of myocardial
perfusion. Study drug was administered through subselec-
tive coronary artery catheters, placed at least 1 cm distal to
the ostium of the target coronary artery. Using contrast
injections, angiographers were required to demonstrate that
no reflux was present from the injection catheter into the
aortic root before and after injection. All films were later
reviewed in a blinded manner by one investigator to deter-
mine whether or not reflux was successfully prevented.
Patients were hospitalized overnight after the procedure
and discharged home the following day. Cardiovascular
medications were stabilized for at least six weeks before
entry into the study, and patients were urged not to alter the
dose of their medication until follow-up was complete.
Follow-up procedures. Outpatient follow-up was under-
taken at two, four, and eight weeks post-treatment. History,
physical examination, ophthalmic examination (8 weeks),
clinical laboratory tests at baseline including hematology,
blood chemistry, urinalysis, 12-lead electrocardiogram, and
serum FGF-4 levels were performed. Diaries containing
information regarding angina attacks and nitroglycerin con-
sumption were collected. Angina class status was recorded
and the Duke Activity Status Index questionnaire was
administered at four and eight weeks. Adverse events were
collected in an ongoing manner.
The main component of the study ended after all patients
had completed the perfusion scan at eight weeks. Patients
were also seen at 3, 6, and 12 months to record significant
adverse events, angina status, and whether they had under-
gone revascularization.
Scintigraphic technique. The primary method to measure
the effect of Ad5FGF-4 on myocardial perfusion was
quantitative Tc-99m sestambi myocardial single-photon
emission computed tomography (SPECT) performed at
rest and then after a standard 6-min intravenous infusion of
adenosine at 140 g/kg/min. Adenosine SPECT was per-
formed at baseline and then repeated at four and eight
weeks post-treatment. Anti-ischemic medications and their
doses were stabilized before baseline SPECT and were held
the morning of each of the three SPECT studies.
The SPECT was performed using a standard rest-stress
protocol whereby 8 to 12 mCi of 99mTc-sestamibi were
injected at rest and images were obtained 1 to 2 h after the
radiopharmaceutical injection to allow for clearance of
99mTc-sestamibi from the liver. After the completion of rest
imaging, the patient underwent adenosine stress with injec-
tion of 25 to 30 mCi of 99mTc-sestamibi at minute 3 into
the infusion. Imaging commenced approximately 1 to 2 h
after adenosine stress. A standard gated SPECT acquisition
protocol was performed using either single- or double-
headed detector systems. For both stress and rest acquisi-
tions, 64 images were obtained over an anterior 180° arc at
25 s/image. For patients weighing more than 250 lbs, a
2-day rest-stress protocol was used with injection of 25 to
30 mCi of 99mTc-sestamibi on each day.
After image acquisition, the raw data SPECT studies
were sent to the core laboratory at Baylor College of
Medicine for processing. All images were reconstructed
using standard back projection with a Butterworth filter at a
40% cutoff (order 5). The images were then reoriented in
the standard three axes for visual review and quantification
(4). Gated SPECT acquisition and processing were per-
formed using the standard Cedars protocol and software (8).
The SPECT quantification was performed by one expe-
rienced investigator (J.J.M.) who was blinded to treatment
assignment. The rest and stress polar maps were indepen-
dently computer-generated and normalized through use of a
circumferential profile analysis. The presence and extent of
count reversibility (ischemia) was determined by subtracting
the raw data stress polar map from the rest polar map on a
pixel-by-pixel basis to generate a “reversibility” polar map.
The stress and reversibility polar maps for each patient were
statistically compared with a corresponding normal database
to determine the stress-induced left ventricular perfusion
defect size, defect severity, and the extent of scintigraphic
scar and ischemia for each of the three studies per patient.
The left ventricular ejection fraction and cardiac volumes
were calculated using the quantitative method described by
Germano et al. (12).
Statistical analysis. Because no previous experience of the
effect of Ad5FGF-4 on perfusion defect size existed, esti-
mation of the sample size was made based on a review of
published data comparing nitroglycerin and placebo (7): the
primary end point was the change from baseline to week 8
in the stress-related RPDS. A 7% difference in the mean
change in RPDS at 8 weeks between Ad5FGF-4 and
placebo was assumed. Using an   0.05 (two-sided) and a
standard deviation of 7%, it was determined that a sample
size of 45 patients (15 on placebo and 30 on active) would
provide 90% power to detect the difference; for a standard
deviation of 8%, power would be 80% for the same
number of patients.
Statistical analysis for the primary (RPDS) and secondary
(total perfusion defect size) end points was undertaken
according to the intention-to-treat (ITT) principle with the
last observation carried forward (LOCF) for missing values.
For between-treatment group comparison, continuous vari-
ables were analyzed using one-way analysis of variance
(ANOVA) or Wilcoxon rank-sum test if data were not
normally distributed, and categorical variables were analyzed
using chi-square or Fisher exact probability test. A one-way
ANOVA model was employed for the between-treatment
group comparison of change from baseline in RPDS. The
Wilcoxon rank-sum test was applied to the between-
treatment group comparison of change from baseline in
total perfusion defect size.
The primary end point analysis was also undertaken,
excluding data from an outlier in the placebo group who had
a 50% (relative) decrease in RPDS (from 31% to 15%) at 4
1341JACC Vol. 42, No. 8, 2003 Grines et al.
October 15, 2003:1339–47 Angiogenesis With Ad5FGF-4 Improves Perfusion
weeks. This analysis was undertaken on clinical grounds. It
was thought that a response of this magnitude could not
occur unless there was non-compliance for antianginal
medication during the pre-treatment period.
The protocol was amended to include an interim analysis
when 22 patients had been treated and followed for 8 weeks.
The purpose of the interim analysis was to terminate the
study based on futility and to permit early planning of a
large study. Investigators, patients, core laboratory physician
and staff, and sponsor’s staff (medical monitor, clinical
research scientists, study biostatistician) remained blinded
to the results of the interim analysis. Congestive heart
failure was defined as fatigue and dyspnea, thrombocytope-
nia was defined as platelet count below the lower limit of
normal, and other laboratory values were considered abnor-
mal if they were not within the normal range.
RESULTS
Patient screening and demographics. Thirteen U.S. hos-
pitals participated. A total of 148 patients were consented,
and 53 patients were randomized. Ninety-five patients were
excluded, 67 because the RPDS was 9%, and 28 for other
reasons (cancer, HIV, withdrawal of consent, angina class 1,
or other entry criteria not met). One randomized patient
underwent angioplasty and dropped out of the study before
receiving the study product. Fifty-two patients were ran-
domized and received Ad5FGF-4, 1010 viral particles (n 
35) or placebo (n  17). All patients were followed for at
least eight weeks after treatment, but one patient refused to
undergo the eight-week post-treatment radionuclide study.
The two groups were well matched (Table 1). The
placebo group had a mean duration of angina of 27 months
versus 19 months for the Ad5FGF-4 group (p  0.35).
Forty-four percent of patients had class 3 angina and 48%
had class 1 to 3 heart failure. The mean left ventricular
ejection fraction was 48%. Forty-six percent of the study
population had three-vessel coronary artery disease, 44%
had two-vessel disease, and 8% had one-vessel disease.
Seventy-three percent of the patients had previous coronary
artery bypass graft (CABG) surgery, and 52% had previous
angioplasty. Twenty-seven percent of the population had
type 2 diabetes, 69% had previous myocardial infarction,
79% had hypertension, and 94% had hyperlipidemia.
Baseline scintigraphic and symptomatic profile of pa-
tients. The mean baseline total perfusion defect size was
32.4%, with 20% reversible ischemia and 12.5% scar. The
mean baseline perfusion stress severity score was 1.2. The
two groups were almost identical regarding the baseline
perfusion characteristics. The mean weekly number of
angina attacks was 6/week, and the mean weekly nitro-
glycerin consumption was 3/week. The most frequent
concomitant medications were beta-blockers, calcium chan-
nel blockers, long-acting nitrates, angiotensin-converting
enzyme inhibitors, and statins. Overall, 82% of patients
were using 2 antianginal drugs, and these medications
remained constant throughout the 8-week post-treatment
period. Statin therapy was started within 6 months before
study drug administration in 3 (19%) placebo patients and 3
(10%) Ad5FGF-4 patients.
Effect of therapy on myocardial perfusion (Table 2). At
8 weeks post-treatment, Ad5FGF-4 reduced RPDS by
4.2% (21% of the baseline value, p  0.001), whereas in the
placebo group, the reduction of RPDS was only 1.6% (8% of
the baseline value, p  0.32) (Figs. 1 and 2). The difference
Table 1. Demographics
Placebo
(n  17)
Ad5FGF-4
(n  35)
p
Value*
Mean age (yrs) 57  8.6 59  8.1 0.54
Gender, male % 88 89 1.00
Race, Caucasian % 94 94 1.00
Hypertension (%) 71 83 0.47
Diabetes (%) 29 26 1.00
CHF (%)† 53 46 0.77
Previous MI (%) 71 69 0.75
Previous CABG (%) 65 77 0.51
Previous angioplasty (%) 65 46 0.25
Three-vessel disease (%) 41 57 0.38
Angina class
2 (%) 59 54 1.00
3 (%) 41 46
Average weekly angina attacks 8  9.1 5  6 0.27
Weekly NTG use 3  3 3  4 0.96
Duration of stable angina (months) 27  32.4 19  24.7 0.35
Mean LVEF (%) 48  10.4 48  10.9 0.98
Mean RPDS (%) 20  8.3 20  9.4 0.91
*p values are based on one-way analysis of variance or Fisher exact test. †CHF was
defined based on dyspnea and fatigue (class 1 to 3).
Ad5FGF-4  adenoviral delivered gene for fibroblast growth factor; CABG 
coronary artery bypass graft; CHF congestive heart failure; LVEF left ventricular
ejection fraction; MI  myocardial infarction; NTG  nitroglycerin; RPDS 
reversible perfusion defect size (single photon emission computed tomography
sestamibi).
Table 2. Perfusion Results Compared With Baseline at 4 and 8 Weeks
Compared With Baseline
4 Weeks 8 Weeks (With LOCF)
Placebo
(n  17)
Ad5FGF-4
(n  35) p*
Placebo
(n  17)
Ad5FGF-4
(n  35) p*
Change in RPDS (ITT) 0.1  6.2 2.7  4.8 0.08 1.6  6.4 4.2  5.6 0.14
Change in RPDS (without 1 outlier on placebo) 1.1  4.8 2.7  4.8 0.01 0.8  5.6 4.2  5.6 0.05
Change in total PDS 1.2  5.7 4.3  5.8 0.03 2.4  6.5 4.6  6.0 0.38
Change in severity 0.03  0.10 0.03  0.11 0.24 0.00  0.09 0.05  0.11 0.12
*p values are based on one-way analysis of variance or the Wilcoxon rank-sum test if the normality assumption was not met.
Ad5FGF-4  adenoviral delivered gene for fibroblast growth factor; ITT  intention to treat; LOCF  last observation carried forward; PDS  perfusion defect size;
RPDS  reversible perfusion defect size.
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between the reduction in RPDS in the Ad5FGF-4 and
placebo groups at eight weeks (primary end point) was not
statistically significant (p  0.14). One patient in the
placebo-treated group was an outlier, and a 50% reduction
compared with the baseline value in RPDS (from 30% to
15%) was observed. This patient was noted to have a much
lower resting and peak heart rate during the intravenous
adenosine infusion at eight weeks post-treatment (54 beats/
min at rest, 71 beats/min at peak) compared with baseline
(70 beats/min at rest, 93 beats/min at peak). Therefore,
poor compliance with antianginal medication during the
pre-treatment period may have accounted for the discrep-
ancy in RPDS. Excluding this patient, a significant differ-
ence in RPDS between the two groups was observed at four
weeks (p  0 .01) and eight weeks after treatment (p 
0.05).
Ad-hoc analysis demonstrated that a larger proportion of
the Ad5FGF-4 group (51% vs. 35% patients, p  0.28)
tended to have a clinically relevant response to treatment
(5% improvement in RPDS), and fewer patients (6% vs.
35%, p  0.01) had clinically relevant worsening (4%
increase in perfusion defect) (Fig. 3). Also, in patients with
a baseline RPDS 20%, there was a significantly greater
improvement, after Ad5FGF-4 (n  19) compared with
patients receiving placebo (n  10), 3.8  5.8 versus 1.6 
4.4, respectively, p  0.009 (Wilcoxon test). Ejection
fraction remained unchanged throughout the study period.
Baseline neutralizing adenoviral antibody titer 100 was
present in 12 of 35 (33%) Ad5FGF-4 patients. However,
perfusion improvements in Ad5FGF-4–treated patients
were not affected by the presence or absence of baseline
neutralizing antibodies 100 (58% and 48% patients im-
proved RPDS 5%, respectively, p  NS).
Effect on angina. Improvement in the mean effect of
subjective angina parameters (angina class, Duke activity
score, weekly angina frequency, and nitroglycerin consump-
tion) was seen in both the placebo and Ad5FGF-4 groups.
Freedom from angina was observed in 30% of the
Ad5FGF-4 group versus 13% of the placebo group. Forty-
three percent of the Ad5FGF-4 group were not taking
nitroglycerin eight weeks post-treatment compared with
17% of the placebo group (Fig. 4).
Safety. A total of 145 intracoronary injections of the study
product were made, and reflux into the aorta was seen
during contrast injection in 10 injections involving 8 (5
active, 3 placebo) patients. However, to opacify the coro-
nary, the contrast injections were made at a higher speed
compared with the study drug. Serum FGF-4 levels were
Figure 1. Representative stress only short-axis (SA) (upper three panels) and vertical long-axis (VLA) (lower three panels) tomographic images of a
patient before therapy (baseline) and at week 4 and week 8. The corresponding quantitative polar maps are shown on the right. The adenosine-induced
ischemic anterior perfusion defect improves dramatically from baseline to week 4 and 8 as reflected by a reduction in perfusion defect size (PDS) from 26%
to 17% to 6%. The ischemic (green) area of the polar map resolves, whereas the scarred region (black) remains unchanged over the eight-week period.
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not detected in any patient at two, four, or eight weeks. The
administration of Ad5FGF-4 was well tolerated. There
were no deaths, myocardial infarctions, episodes of myocar-
ditis, allergic reactions, or symptomatic hypotension during
Ad5FGF-4 administration or at follow-up. Serious adverse
events (mostly unrelated) were reported in 13 patients
(Table 3). One patient who received Ad5FGF-4 developed
transient fever associated with back pain, myalgia, a tran-
sient rise in serum total bilirubin to 1.8 mg/dl (direct 0.6
mg/dl), and a transient fall in platelet count to 144,000/l
Figure 2. Absolute improvement in perfusion defect size at eight weeks post-treatment: Ad5FGF-4 reduced the total and reversible perfusion defect size
(RPDS) by 4.6% and 4.2%, respectively (p  0.001). In the placebo group, the reductions were only 2.4% (p  0.14) and 1.6% (p  0.32), respectively.
However, the difference between Ad5FGF-4 and placebo was not significantly different. White bars  Ad5FGF-4; black bars  placebo.
Figure 3. Change in myocardial perfusion at eight weeks: a greater percentage improvement (compared with baseline) in both reversible and total perfusion
defect size was seen in the Ad5FGF-4 group compared with the placebo group. Moreover, a greater number of Ad5FGF-4 patients had a clinically relevant
improvement in perfusion (5% improvement), and significantly fewer Ad5FGF-4 patients had clinically relevant worsening (4% increase in defect size)
of perfusion (6% vs. 35%, p  0.01). White bars  Ad5FGF-4; black bars  placebo.
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(normal range 150,000/l to 400,000/l). Both laboratory
parameters corrected spontaneously within two weeks. One
patient who received Ad5FGF-4 developed a rise in liver
enzymes at week 2. The patient tested positive for hepatitis
C; however, the study product and its precursor cell and
viral banks tested negative for hepatitis C, thus excluding
the study product as a possible cause.
Transient, mild (between one and two times the upper
limit of normal) increases in serum transaminases (serum
glutamic-oxaloacetic transaminase [SGOT] and serum
glutamic-pyruvic transaminase [SGPT]) were noted in a
few patients. The SGOT levels increased in 3 patients on
placebo and in 10 patients on Ad5FGF-4. The SGPT levels
increased in 5 patients on placebo and in 10 patients on
Ad5FGF-4. Mild CK increases occurred in 5 patients on
placebo and in 8 patients on Ad5FGF-4. These were
considered to be statin-related. There were no correspond-
ing increases in troponin T and no clinical or electrocardio-
graphic evidence of myocarditis. Platelet counts decreased
transiently in six patients (one on placebo, five on Ad5FGF-
4). In only one of these the count fell below 100,000/l (the
patient received Ad5FGF-4). This patient had normal
marrow histology, and his count returned to normal.
One patient, in the Ad5FGF-4 group, developed tran-
sient worsening of congestive heart failure 45 days after
treatment. One diabetic patient who received Ad5FGF-4
developed worsening angina and on repeat angiography 154
days after treatment was found to have progression of
proximal left anterior descending coronary artery stenosis
and underwent angioplasty. A second patient in the active
group developed worsening angina and received CABG
surgery. Four patients receiving placebo developed worsen-
Figure 4. Symptomatic improvements at eight weeks post-treatment: a greater percentage of Ad5FGF-4 patients (compared with placebo) had
symptomatic improvement, with 30% of patients having no angina and 43% of patients using no nitroglycerin (NTG) at eight weeks; however, these
differences were not significant. White bars  Ad5FGF-4; black bars  placebo.
Table 3. Adverse Events
Serious Events (Related or Unrelated)
and Laboratory Abnormalities*
Placebo (n  17) Ad5FGF-4 (n  35)
N % N %
Fever with low platelet count 0 0 1 2.8
Worsening or unstable angina† 4 24 2 6
Required angioplasty or CABG 3 18 2 6
Carotid endarterectomy 0 0 1 3
Hepatitis C 0 0 1 3
Worsening CHF 0 0 1 3
Ulcerative colitis 1 6 0 0
Post-laminectomy syndrome 0 0 1 3
Depression 0 0 1 3
Asthmatic bronchitis 0 0 1 3
Increase in SGOT‡ 3 18 10 29
Increase in SGPT‡ 5 29 10 29
Increase in CK§ 5 29 8 23
Reduction of platelet count§ 1 6 5 14
*Up to 12 months follow-up for all data available. No significant differences. †p  0.06 (chi-square). ‡2 times the upper limit
of normal. §Outside of normal range.
CK  creatine kinase; SGOT  serum glutamic-oxaloacetic transaminase; SGPT  serum glutamic-pyruvic transaminase.
Other abbreviations as in Table 1.
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ing angina; three of these four required angioplasty. Overall,
the Ad5FGF-4 group had a lower incidence of worsening or
unstable angina (6% vs. 24%) or revascularization proce-
dures (6% vs. 18%) compared with the placebo group.
A patient in the placebo group experienced abdominal
pain and bloody diarrhea due to ulcerative colitis. One
patient in the Ad5FGF-4 group had a skin lesion (squa-
mous cell carcinoma) removed from his nose. He had several
skin lesions removed previously; these had been considered
premalignant (actinic keratoses), but histopathology was
never performed. There was no evidence of retinal neovas-
cularization or angioma formation.
DISCUSSION
Although SPECT myocardial perfusion has been used in
other studies of angiogenesis, these trials were either not
randomized or blinded (13,14) or showed no improvement
in perfusion (1). In addition, these trials utilized a short-
lived infusion of protein instead of the gene encoding for the
protein. The current study is the first randomized placebo-
controlled trial to test the effect of gene therapy for
angiogenesis on myocardial perfusion in humans. We found
that in a carefully selected patient group with severe coro-
nary artery disease, persistent angina despite optimum
antianginal medication, and pharmacologically induced
myocardial ischemia, a dose of 1010 particles of Ad5FGF-4
injected into the coronary circulation resulted in a clinically
relevant (21% increase from baseline value) and significant
(p  0.001) improvement in stress-induced myocardial
perfusion at eight weeks compared with baseline. However,
the increase in stress-induced myocardial perfusion defect,
compared with placebo, was not significant (21% relative
reduction in defect size for Ad5FGF-4 vs. 8% for placebo,
p  0.14). When a single outlier in the placebo group who
had a 50% improvement in stress-related perfusion (com-
pared with baseline value) was excluded, a significant benefit
was observed (p  0.05). Improvements 25% of baseline
values are not expected in the absence of revascularization or
antianginal therapy (7,8). The likely cause of this unex-
pected improvement appears to be irregular compliance to
antianginal medications during the baseline period. More-
over, ad-hoc analysis suggested a significant benefit in
avoiding the worsening of perfusion (p  0.01) (Fig. 2), as
well as a significantly greater decrease in RPDS in patients
with baseline RPDS  20% (p  0.009).
The current study was designed to minimize the biologic
variability of ischemia through two approaches. First, pa-
tients were required to be on a stable pharmacologic
regimen for a baseline period of up to six weeks before
administration of the study drug. Second, myocardial per-
fusion was assessed at a core laboratory in a blinded fashion
using a highly reproducible technique. Finally, only patients
with clinically relevant reversible perfusion defects of 9%
were included (9).
In the current study, intracoronary administration of
Ad5FGF-4 was safe and well tolerated. Circulating FGF-4
was not detected. Post-treatment surveillance was intense
because of concerns about the possible risks from an
exogenously administered gene encoding an angiogenic
protein. During the follow-up period, there was no evidence
of retinal neovascularization or angioma formation. One
skin malignancy was diagnosed in a patient who had
previously had premalignant lesions (actinic keratosis),
which were excised but not subjected to histopathology.
One patient developed worsening angina associated with
progression of stenosis that was reported as a possible
consequence of placement of the subselective coronary
catheter or intracoronary injection, but natural progression
in this diabetic patient with three-vessel coronary disease
cannot be ruled out.
The current study should be regarded as exploratory. The
sample size was small, and effects of angiogenic growth
factor therapy on quantitatively determined SPECT defect
size have not previously been studied. The statistical as-
sumption used to determine the power of the trial included
a 7% absolute difference in perfusion defect size. This
assumption was derived from a previous study of transder-
mal nitrate therapy in patients with stable angina who had
no previous myocardial infarction and no regional or global
left ventricular function abnormalities at rest. In addition,
antianginal drugs were stopped in the majority (80%) of
patients in that study (7). Whether this difference actually
represents statistical underpowering of the current study
based on an effect observed with a treatment with a different
mechanism of action (dilation of epicardial conduit vessels)
or is a consequence of the spatial resolution of tomographic
scintigraphy is not known. Although myocardial scintigra-
phy using adenosine stress and tomographic sestamibi
imaging has been shown to reflect the distribution of blood
flow seen with radioactive microspheres, it may not be
adequate to detect the growth of fine collateral networks and
could have underestimated the effects of an angiogenic
growth factor.
Unlike our earlier study (3), the presence of adenoviral
neutralizing antibodies at baseline appeared to have no
influence on improvement in myocardial perfusion. Finally,
recent blinded studies of new therapies for advanced isch-
emic heart disease have established the magnitude of pla-
cebo effect. In each randomized, blinded study of growth
factors or transmyocardial laser revascularization, significant
improvements in exercise time and anginal status were
reported in placebo-treated patients (1–3). Similarly, in the
current study, the placebo-treated group had symptomatic
improvement, less nitrate use, but non-significant improve-
ment in RPDS.
Given these constraints, the findings of a significant
reduction in defect size after treatment with Ad5FGF-4,
the trend toward a greater reduction than with placebo, and
significantly fewer patients in whom worsening of the
ischemic defect size was observed should be regarded as
positive signals regarding efficacy of the drug. Consequently,
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larger trials exploring the effect of Ad5FGF-4 on clinical
outcomes are warranted.
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